Immunotherapy Colitis & Severe Diarrhea Management

Immune checkpoint inhibitor drugs work by releasing the brakes on your immune system so it can recognize and attack cancer. The same change can let the immune system attack healthy tissue. The National Cancer Institute (NCI) groups these reactions together as organ-related inflammation and names each one after the organ involved, using the ending "-itis." When the bowel is affected, it is called colitis.

NCI describes it directly: "Inflammation to organs in your digestive system, called colitis, may cause stomach or abdominal pain, diarrhea, and black or bloody stools."

That is inflammation of the bowel wall itself, not simply a change in how food moves through you. It is a different problem from the loose stools that many cancer treatments cause, and it is treated differently.

NCI defines plain diarrhea as "having bowel movements (stools) more often than normal. The stool may also be soft, loose, or watery." Colitis can start looking exactly like that. What NCI adds to the colitis description are the features that ordinary diarrhea does not usually bring: stomach or abdominal pain, and black or bloody stools.

You cannot reliably tell the two apart at home, and you are not expected to. NCI's instruction is that "it's important to have any possible inflammatory problems assessed by your oncologist."

The U.S. National Library of Medicine's patient information for checkpoint inhibitor drugs is explicit. For pembrolizumab it states: "Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment," and the symptoms listed include "Diarrhea; stools that are black, tarry, sticky, or contain blood or mucus; or severe abdominal pain."

The equivalent instruction for ipilimumab is the same — "call your doctor immediately or get emergency medical treatment" — and its list reads "diarrhea, bloody or black, tarry, sticky stools, severe stomach pain or tenderness, or fever."

Read what that instruction does and does not say. It is triggered by diarrhea itself. It does not ask you to reach a certain number of stools first, and it does not tell you to wait and see whether it settles.

On numbers: NCI grades treatment-related diarrhea by how far it exceeds your own baseline. "Grades 1 and 2 (having up to six bowel movements above your normal daily number) can usually be managed at home, but grades 3 and 4 (having seven or more bowel movements above your normal daily number) can be life-threatening and may require treatment in a hospital." Those grades come from NCI's general diarrhea guidance rather than from a checkpoint-inhibitor-specific rule, so treat seven or more above your normal as clearly serious — not as the point at which reporting begins.

NCI also notes that your oncologist "may advise you to call him or her first about inflammatory symptoms, or you may be advised to seek emergency medical care." Ask which applies to you before you need it.

Because the problem is an overactive immune response, the treatment aims at the immune system rather than at the bowel. NCI puts it plainly: "Sometimes these side effects are managed with medicines, such as steroids, that work to slow down an overactive immune response."

This is standard, not a sign that something has gone badly wrong. In FDA labeling for pembrolizumab, systemic corticosteroids were required in 69% of patients who developed colitis. The labeled approach is prednisone at 1 to 2 mg/kg/day, or an equivalent, continued until the reaction improves to Grade 1 or less and then tapered over at least one month, with the drug withheld or permanently discontinued depending on severity.

This is the part people miss. FDA labeling states that "immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody," and that while they usually appear during treatment, they "can also manifest after discontinuation."

So if bowel symptoms begin weeks or months after your final infusion, they are still worth reporting, and the team who gave you the immunotherapy needs to know. Whoever you see — an urgent care clinician, an emergency doctor, your primary care physician — tell them the name of the immunotherapy drug you received and when you last had it. That single fact changes how they think about your symptoms.

• National Cancer Institute — Immunotherapy and Organ-Related Inflammation: https://www.cancer.gov/about-cancer/treatment/side-effects/organ-inflammation
• National Cancer Institute — Diarrhea: https://www.cancer.gov/about-cancer/treatment/side-effects/diarrhea
• MedlinePlus (National Library of Medicine) — Pembrolizumab Injection: https://medlineplus.gov/druginfo/meds/a614048.html
• MedlinePlus (National Library of Medicine) — Ipilimumab Injection: https://medlineplus.gov/druginfo/meds/a611023.html
• U.S. Food and Drug Administration — KEYTRUDA (pembrolizumab) prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125514s158lbl.pdf

---

<script type="application/ld+json"> { "@context": "https://schema.org", "@type": "MedicalWebPage", "headline": "Immunotherapy Colitis & Severe Diarrhea Management", "description": "How immune checkpoint inhibitor colitis differs from ordinary treatment diarrhea, the symptoms that require calling your doctor immediately, why steroids are used, and why it can begin after treatment ends.", "url": "https://cancerexplained.org/side-effects/immunotherapy-colitis-and-severe-diarrhea", "datePublished": "2026-07-23", "dateModified": "2026-07-28", "publisher": { "@type": "Organization", "name": "Cancer Explained", "url": "https://cancerexplained.org" }, "author": { "@type": "Organization", "name": "Cancer Explained Editorial Team" }, "medicalAudience": "Patient", "aspect": "Cancer Information and Support" } </script>